Resource Summary Report

Generated by FDI Lab - SciCrunch.org on Apr 27, 2025

CD 45R (b220)

RRID:AB_393581
Type: Antibody

Proper Citation

(BD Biosciences Cat# 550286, RRID:AB_393581)

Antibody Information

URL: http://antibodyregistry.org/AB_393581

Proper Citation: (BD Biosciences Cat# 550286, RRID:AB_393581)

Target Antigen: A suspension of Abelson murine leukemia virus-induced pre-B tumor cells.

Host Organism: rat

Clonality: monoclonal

Comments: Immunohistochemistry-frozen, Immunohistochemistry-paraffin, Western blot Info: Independent validation by the NYU Lagone was performed for: IHC. This antibody was found to have the following characteristics: Functional in human:FALSE, NonFunctional in human:FALSE, Functional in animal:TRUE, NonFunctional in animal:FALSE

Antibody Name: CD 45R (b220)

Description: This monoclonal targets A suspension of Abelson murine leukemia virus-induced pre-B tumor cells.

Clone ID: [RA3-6B2]

Antibody ID: AB_393581

Vendor: BD Biosciences

Catalog Number: 550286

Record Creation Time: 20241016T223558+0000

Record Last Update: 20241016T231115+0000

Ratings and Alerts

- Independent validation by the NYU Lagone was performed for: IHC. This antibody was found to have the following characteristics: Functional in human:FALSE, NonFunctional in human:FALSE, Functional in animal:TRUE, NonFunctional in animal:FALSE - NYU Langone's Center for Biospecimen Research and Development https://med.nyu.edu/research/scientific-cores-shared-resources/center-biospecimen-research-development

No alerts have been found for CD 45R (b220).

Data and Source Information

Source: Antibody Registry

Usage and Citation Metrics

We found 36 mentions in open access literature.

Listed below are recent publications. The full list is available at FDI Lab - SciCrunch.org.

Gaballa A, et al. (2024) PAF1c links S-phase progression to immune evasion and MYC function in pancreatic carcinoma. Nature communications, 15(1), 1446.

Barisic D, et al. (2024) ARID1A orchestrates SWI/SNF-mediated sequential binding of transcription factors with ARID1A loss driving pre-memory B cell fate and lymphomagenesis. Cancer cell.

Diehl C, et al. (2024) Hyperreactive B cells instruct their elimination by T cells to curb autoinflammation and lymphomagenesis. Immunity.

Bolini L, et al. (2024) Long-term recruitment of peripheral immune cells to brain scars after a neonatal insult. Glia, 72(3), 546.

Swisa A, et al. (2024) The evolutionarily ancient FOXA transcription factors shape the murine gut microbiome via control of epithelial glycosylation. Developmental cell, 59(16), 2069.

Venturutti L, et al. (2023) An Aged/Autoimmune B-cell Program Defines the Early Transformation of Extranodal Lymphomas. Cancer discovery, 13(1), 216.

Carraro C, et al. (2023) Chromatin accessibility profiling of targeted cell populations with laser capture microdissection coupled to ATAC-seq. Cell reports methods, 3(10), 100598.

López-Sanz L, et al. (2023) The presence of activating IgG Fc receptors in macrophages

aggravates the development of experimental abdominal aortic aneurysm. Clinica e investigacion en arteriosclerosis : publicacion oficial de la Sociedad Espanola de Arteriosclerosis.

Li J, et al. (2023) Cooperative super-enhancer inactivation caused by heterozygous loss of CREBBP and KMT2D skews B cell fate decisions and yields T cell-depleted lymphomas. bioRxiv : the preprint server for biology.

Durfee C, et al. (2023) Human APOBEC3B promotes tumor development in vivo including signature mutations and metastases. Cell reports. Medicine, 4(10), 101211.

Durfee C, et al. (2023) Human APOBEC3B promotes tumor heterogeneity in vivo including signature mutations and metastases. bioRxiv : the preprint server for biology.

Tshering LF, et al. (2023) Immune mechanisms shape the clonal landscape during early progression of prostate cancer. Developmental cell, 58(12), 1071.

Griger J, et al. (2023) An integrated cellular and molecular model of gastric neuroendocrine cancer evolution highlights therapeutic targets. Cancer cell, 41(7), 1327.

Fischer A, et al. (2023) In vivo interrogation of regulatory genomes reveals extensive quasi-insufficiency in cancer evolution. Cell genomics, 3(3), 100276.

Asrir A, et al. (2022) Tumor-associated high endothelial venules mediate lymphocyte entry into tumors and predict response to PD-1 plus CTLA-4 combination immunotherapy. Cancer cell, 40(3), 318.

Al Moussawi K, et al. (2022) Mutant Ras and inflammation-driven skin tumorigenesis is suppressed via a JNK-iASPP-AP1 axis. Cell reports, 41(3), 111503.

Dutt TS, et al. (2022) Mucosal exposure to non-tuberculous mycobacteria elicits B cell-mediated immunity against pulmonary tuberculosis. Cell reports, 41(11), 111783.

Maderna C, et al. (2022) A murine model of cerebral cavernous malformations with acute hemorrhage. iScience, 25(3), 103943.

Leung W, et al. (2022) SETD2 Haploinsufficiency Enhances Germinal Center-Associated AICDA Somatic Hypermutation to Drive B-cell Lymphomagenesis. Cancer discovery, 12(7), 1782.

Bernal S, et al. (2021) Protective effect of suppressor of cytokine signalling 1-based therapy in experimental abdominal aortic aneurysm. British journal of pharmacology, 178(3), 564.